Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEX vs FEC 100 as Neoadjuvant Therapy in Operable Breast Cancer
NCT02846428Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2004
- Primary completion
- Dec 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Roche. Started Mar 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02846428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846428.